TWI404545B - 含有黃酮類化合物及黃烷之口腔護理組合物 - Google Patents
含有黃酮類化合物及黃烷之口腔護理組合物 Download PDFInfo
- Publication number
- TWI404545B TWI404545B TW94145428A TW94145428A TWI404545B TW I404545 B TWI404545 B TW I404545B TW 94145428 A TW94145428 A TW 94145428A TW 94145428 A TW94145428 A TW 94145428A TW I404545 B TWI404545 B TW I404545B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- agent
- oral
- weight
- flavan
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 247
- 229930003935 flavonoid Natural products 0.000 title claims description 105
- 235000017173 flavonoids Nutrition 0.000 title claims description 105
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 title claims description 90
- 150000002215 flavonoids Chemical class 0.000 title claims description 28
- 239000003623 enhancer Substances 0.000 claims description 76
- -1 flavonoid compound Chemical class 0.000 claims description 52
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000013543 active substance Substances 0.000 claims description 26
- 230000002708 enhancing effect Effects 0.000 claims description 26
- 210000000214 mouth Anatomy 0.000 claims description 26
- 239000003242 anti bacterial agent Substances 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 18
- 239000004599 antimicrobial Substances 0.000 claims description 17
- 230000014759 maintenance of location Effects 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 17
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 15
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 15
- 239000002324 mouth wash Substances 0.000 claims description 14
- 229940051866 mouthwash Drugs 0.000 claims description 14
- 239000000606 toothpaste Substances 0.000 claims description 14
- 125000002091 cationic group Chemical group 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 13
- 239000003906 humectant Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 229940034610 toothpaste Drugs 0.000 claims description 12
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 11
- 229920005646 polycarboxylate Polymers 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 125000000129 anionic group Chemical group 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 10
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 8
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 claims description 7
- 208000006558 Dental Calculus Diseases 0.000 claims description 7
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 7
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 claims description 7
- 229950010221 alexidine Drugs 0.000 claims description 7
- 230000000181 anti-adherent effect Effects 0.000 claims description 7
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 7
- 239000004075 cariostatic agent Substances 0.000 claims description 7
- 239000000551 dentifrice Substances 0.000 claims description 7
- 230000004968 inflammatory condition Effects 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 229960001950 benzethonium chloride Drugs 0.000 claims description 6
- 229960003260 chlorhexidine Drugs 0.000 claims description 6
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 claims description 6
- 229960001915 hexamidine Drugs 0.000 claims description 6
- 229960004867 hexetidine Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims description 6
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003500 triclosan Drugs 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000003925 fat Substances 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 229960001774 octenidine Drugs 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 239000000899 Gutta-Percha Substances 0.000 claims description 4
- 229920001007 Nylon 4 Polymers 0.000 claims description 4
- 240000000342 Palaquium gutta Species 0.000 claims description 4
- 150000001767 cationic compounds Chemical class 0.000 claims description 4
- 229920000588 gutta-percha Polymers 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 claims description 4
- 229960002799 stannous fluoride Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 2
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 claims description 2
- CKUJRAYMVVJDMG-IYEMJOQQSA-L (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;tin(2+) Chemical compound [Sn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CKUJRAYMVVJDMG-IYEMJOQQSA-L 0.000 claims description 2
- OQBLGYCUQGDOOR-UHFFFAOYSA-L 1,3,2$l^{2}-dioxastannolane-4,5-dione Chemical compound O=C1O[Sn]OC1=O OQBLGYCUQGDOOR-UHFFFAOYSA-L 0.000 claims description 2
- GEZAUFNYMZVOFV-UHFFFAOYSA-J 2-[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetan-2-yl)oxy]-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetane 2-oxide Chemical compound [Sn+2].[Sn+2].[O-]P([O-])(=O)OP([O-])([O-])=O GEZAUFNYMZVOFV-UHFFFAOYSA-J 0.000 claims description 2
- NCVGSSQICKMAIA-UHFFFAOYSA-N 2-heptadecyl-4,5-dihydro-1h-imidazole Chemical compound CCCCCCCCCCCCCCCCCC1=NCCN1 NCVGSSQICKMAIA-UHFFFAOYSA-N 0.000 claims description 2
- USYAMXSCYLGBPT-UHFFFAOYSA-L 3-carboxy-3-hydroxypentanedioate;tin(2+) Chemical compound [Sn+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O USYAMXSCYLGBPT-UHFFFAOYSA-L 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229940026651 gly-oxide Drugs 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- COALSIYJQHMCDX-UHFFFAOYSA-L propanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)CC([O-])=O COALSIYJQHMCDX-UHFFFAOYSA-L 0.000 claims description 2
- 235000011150 stannous chloride Nutrition 0.000 claims description 2
- 239000001119 stannous chloride Substances 0.000 claims description 2
- 229940007163 stannous tartrate Drugs 0.000 claims description 2
- FIGVVZUWCLSUEI-UHFFFAOYSA-N tricosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCC FIGVVZUWCLSUEI-UHFFFAOYSA-N 0.000 claims 4
- 150000001298 alcohols Chemical class 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 229960003589 arginine hydrochloride Drugs 0.000 claims 1
- PNOXNTGLSKTMQO-UHFFFAOYSA-L diacetyloxytin Chemical compound CC(=O)O[Sn]OC(C)=O PNOXNTGLSKTMQO-UHFFFAOYSA-L 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004387 flavanoid group Chemical group 0.000 claims 1
- 150000008040 ionic compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940063675 spermine Drugs 0.000 claims 1
- 239000008375 oral care agent Substances 0.000 description 32
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 230000002272 anti-calculus Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 229920000388 Polyphosphate Polymers 0.000 description 10
- 239000001205 polyphosphate Substances 0.000 description 10
- 235000011176 polyphosphates Nutrition 0.000 description 10
- 210000003296 saliva Anatomy 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000013355 food flavoring agent Nutrition 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 235000013772 propylene glycol Nutrition 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000002562 thickening agent Substances 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 208000007565 gingivitis Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 201000001245 periodontitis Diseases 0.000 description 7
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 235000010356 sorbitol Nutrition 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000003082 abrasive agent Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 229940091249 fluoride supplement Drugs 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000811 xylitol Substances 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- 235000010447 xylitol Nutrition 0.000 description 5
- 229960002675 xylitol Drugs 0.000 description 5
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 4
- 229940123208 Biguanide Drugs 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 4
- 229940015301 baicalein Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000218378 Magnolia Species 0.000 description 3
- 240000007673 Origanum vulgare Species 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 108010077895 Sarcosine Proteins 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000002882 anti-plaque Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 3
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003975 dentin desensitizing agent Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 239000004034 viscosity adjusting agent Substances 0.000 description 3
- GUGRJSRVFMFOPH-HLGMLANZSA-N (8R,9S,10S,13S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12-decahydro-1H-cyclopenta[a]phenanthrene-3,17-diol Chemical compound C[C@@]12C(=CC=C1[C@@H]1CCC3CC(CC[C@]3(C)[C@H]1CC2)O)O GUGRJSRVFMFOPH-HLGMLANZSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000013628 Lantana involucrata Nutrition 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004907 Macro-emulsion Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- 208000003076 Osteolysis Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 2
- 101710156627 Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003610 anti-gingivitis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 description 2
- 229910001632 barium fluoride Inorganic materials 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 239000008376 breath freshener Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- SAEOCANGOMBQSP-UHFFFAOYSA-N diazanium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [NH4+].[NH4+].[O-]P([O-])(F)=O SAEOCANGOMBQSP-UHFFFAOYSA-N 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 150000005833 flavanes Chemical class 0.000 description 2
- 235000011987 flavanols Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000006950 reactive oxygen species formation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 229940071089 sarcosinate Drugs 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 2
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- ONLXDDXNWDCHRV-AWEZNQCLSA-N (2s)-2-anilino-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC=1C=CC=CC=1)C1=CC=CC=C1 ONLXDDXNWDCHRV-AWEZNQCLSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- SMOHSULBMKXDEN-RVDMUPIBSA-N (e)-1-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-2-nitro-1-n'-prop-2-ynylethene-1,1-diamine Chemical compound CN(C)CC1=CC=C(CSCCN\C(NCC#C)=C\[N+]([O-])=O)O1 SMOHSULBMKXDEN-RVDMUPIBSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 1
- KZYJXZMFIHHEML-UHFFFAOYSA-N 1-chlorohexadecane;pyridine Chemical compound C1=CC=NC=C1.CCCCCCCCCCCCCCCCCl KZYJXZMFIHHEML-UHFFFAOYSA-N 0.000 description 1
- KEDVUOWPLAHMLZ-UHFFFAOYSA-N 1-cyano-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-2-prop-2-ynylguanidine Chemical compound CC=1NC=NC=1CSCCNC(NC#N)=NCC#C KEDVUOWPLAHMLZ-UHFFFAOYSA-N 0.000 description 1
- YDDXVAXDYKBWDX-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-4-thiazolyl]methylthio]ethyl]-2-methylguanidine Chemical compound N#CNC(=NC)NCCSCC1=CSC(N=C(N)N)=N1 YDDXVAXDYKBWDX-UHFFFAOYSA-N 0.000 description 1
- QYXHFICHKVRPSH-UHFFFAOYSA-N 1-cyano-3-[4-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]butyl]-2-methylguanidine Chemical compound N#CN=C(NC)NCCCCC1=CSC(NC(N)=N)=N1 QYXHFICHKVRPSH-UHFFFAOYSA-N 0.000 description 1
- GSSDUXHQPXODCN-UHFFFAOYSA-N 1-phenylethenylphosphonic acid Chemical compound OP(O)(=O)C(=C)C1=CC=CC=C1 GSSDUXHQPXODCN-UHFFFAOYSA-N 0.000 description 1
- CTMBNCSHOCVHMK-UHFFFAOYSA-M 1-pyridin-1-ium-1-ylhexadecan-1-one;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC(=O)[N+]1=CC=CC=C1 CTMBNCSHOCVHMK-UHFFFAOYSA-M 0.000 description 1
- YFVBASFBIJFBAI-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 YFVBASFBIJFBAI-UHFFFAOYSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- DXENBVSHQHBTBD-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-1-(diaminomethylidene)guanidine Chemical compound NC(N)=NC(N)=NCC1=CC=C(Cl)C=C1 DXENBVSHQHBTBD-UHFFFAOYSA-N 0.000 description 1
- GIMNAEMRNXUAQP-UHFFFAOYSA-N 2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine Chemical compound N1C(C)=NC=C1C1=CSC(N=C(N)N)=N1 GIMNAEMRNXUAQP-UHFFFAOYSA-N 0.000 description 1
- RWMSXNCJNSILON-UHFFFAOYSA-N 2-[4-(2-propylpentyl)piperidin-1-yl]ethanol Chemical compound CCCC(CCC)CC1CCN(CCO)CC1 RWMSXNCJNSILON-UHFFFAOYSA-N 0.000 description 1
- JDKAFLSRQPKFCQ-UHFFFAOYSA-N 2-[4-[2-[(4-amino-1-oxo-1,2,5-thiadiazol-3-yl)amino]ethylsulfanylmethyl]-1,3-thiazol-2-yl]guanidine Chemical compound S1C(N=C(N)N)=NC(CSCCNC=2C(=NS(=O)N=2)N)=C1 JDKAFLSRQPKFCQ-UHFFFAOYSA-N 0.000 description 1
- BKTDITUACHTMQR-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;oxalic acid Chemical compound OC(=O)C(O)=O.OCCN(CCO)CCO BKTDITUACHTMQR-UHFFFAOYSA-N 0.000 description 1
- TYBHZVUFOINFDV-UHFFFAOYSA-N 2-bromo-6-[(3-bromo-5-chloro-2-hydroxyphenyl)methyl]-4-chlorophenol Chemical compound OC1=C(Br)C=C(Cl)C=C1CC1=CC(Cl)=CC(Br)=C1O TYBHZVUFOINFDV-UHFFFAOYSA-N 0.000 description 1
- MTPIQEWGULCIPM-UHFFFAOYSA-N 2-ethylhexyl 3,4,5-trihydroxybenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC(O)=C(O)C(O)=C1 MTPIQEWGULCIPM-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- TUACCPOORFWMSA-UHFFFAOYSA-N 2-phenyl-4h-chromene-2,3,3-triol Chemical class OC1(O)CC2=CC=CC=C2OC1(O)C1=CC=CC=C1 TUACCPOORFWMSA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KSBYXRUNSLGUNE-UHFFFAOYSA-N 3-amino-4-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]cyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(N)=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 KSBYXRUNSLGUNE-UHFFFAOYSA-N 0.000 description 1
- IZTBLLPMEZOKSV-UHFFFAOYSA-N 3-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-oxo-1,2,5-thiadiazole-3,4-diamine Chemical compound O1C(CN(C)C)=CC=C1CSCCNC1=NS(=O)N=C1N IZTBLLPMEZOKSV-UHFFFAOYSA-N 0.000 description 1
- YVFNSFYHKSSVRN-UHFFFAOYSA-N 3-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,2,5-thiadiazole-3,4-diamine;hydrochloride Chemical compound Cl.NC1=NSN=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 YVFNSFYHKSSVRN-UHFFFAOYSA-N 0.000 description 1
- PPMYJUCFCTXGKV-UHFFFAOYSA-N 3-n-[3-[3-[(4-methylpiperidin-1-yl)methyl]phenoxy]propyl]-1-oxo-1,2,5-thiadiazole-3,4-diamine Chemical compound C1CC(C)CCN1CC1=CC=CC(OCCCNC=2C(=NS(=O)N=2)N)=C1 PPMYJUCFCTXGKV-UHFFFAOYSA-N 0.000 description 1
- ZGDUCQLHZPXPLO-UHFFFAOYSA-N 4-(3,4-dihydro-2h-chromen-2-yl)benzene-1,2-diol Chemical compound C1=C(O)C(O)=CC=C1C1OC2=CC=CC=C2CC1 ZGDUCQLHZPXPLO-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ANAAMBRRWOGKGU-UHFFFAOYSA-M 4-ethyl-1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(CC)C=C1 ANAAMBRRWOGKGU-UHFFFAOYSA-M 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- ALCSGJCIESECFD-UHFFFAOYSA-N 5-[3-[[amino(2,2,2-trifluoroethylimino)methyl]amino]-1-pyrazolyl]pentanamide Chemical compound NC(=O)CCCCN1C=CC(NC(N)=NCC(F)(F)F)=N1 ALCSGJCIESECFD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical class N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BOXRWDRUTMXDRW-UHFFFAOYSA-N CCCCCCCCCCCCCCCCO.F Chemical compound CCCCCCCCCCCCCCCCO.F BOXRWDRUTMXDRW-UHFFFAOYSA-N 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021593 Copper(I) fluoride Inorganic materials 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241001065700 Ficus glabrata Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000005385 Intramolecular Transferases Human genes 0.000 description 1
- 108010031311 Intramolecular Transferases Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KMZQAVXSMUKBPD-DJWKRKHSSA-N Lafutidine Chemical compound C=1C=COC=1C[S+]([O-])CC(=O)NC\C=C/COC(N=CC=1)=CC=1CN1CCCCC1 KMZQAVXSMUKBPD-DJWKRKHSSA-N 0.000 description 1
- NRIGRKAXOLMTSK-UHFFFAOYSA-N Lamtidine Chemical compound CN1N=C(N)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 NRIGRKAXOLMTSK-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SRIJLARXVRHZKD-UHFFFAOYSA-N OP(O)=O.C=CC1=CC=CC=C1 Chemical class OP(O)=O.C=CC1=CC=CC=C1 SRIJLARXVRHZKD-UHFFFAOYSA-N 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006669 Origanum minutiflorum Nutrition 0.000 description 1
- 241001518075 Origanum minutiflorum Species 0.000 description 1
- 235000004383 Origanum vulgare subsp. vulgare Nutrition 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- GHNYJNFZXNTXEH-UHFFFAOYSA-M [Cl-].C(C(C)C)C(C1=CC=CC=C1)([N+](C)(C)OC1=CC=CC=C1)CC(C)C Chemical compound [Cl-].C(C(C)C)C(C1=CC=CC=C1)([N+](C)(C)OC1=CC=CC=C1)CC(C)C GHNYJNFZXNTXEH-UHFFFAOYSA-M 0.000 description 1
- HFIGWKOFZLNOQK-UHFFFAOYSA-K [O-]P([O-])(=O)OP(=O)([O-])O.[Ca+2].[Na+] Chemical class [O-]P([O-])(=O)OP(=O)([O-])O.[Ca+2].[Na+] HFIGWKOFZLNOQK-UHFFFAOYSA-K 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- LDDQLRUQCUTJBB-UHFFFAOYSA-N ammonium fluoride Chemical class [NH4+].[F-] LDDQLRUQCUTJBB-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 229950002342 bisfentidine Drugs 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- QSFOWAYMMZCQNF-UHFFFAOYSA-N delmopinol Chemical compound CCCC(CCC)CCCC1COCCN1CCO QSFOWAYMMZCQNF-UHFFFAOYSA-N 0.000 description 1
- 229960003854 delmopinol Drugs 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- MURUHMTVTKOWBY-UHFFFAOYSA-N donetidine Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(NC1=O)=NC=C1CC1=CC(=O)NC=C1 MURUHMTVTKOWBY-UHFFFAOYSA-N 0.000 description 1
- 229950010956 donetidine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 1
- 229950002377 ebrotidine Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- ZTWTYVWXUKTLCP-UHFFFAOYSA-L ethenyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-L 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229940080646 ethylhexyl gallate Drugs 0.000 description 1
- 229950007285 etintidine Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- MURRAGMMNAYLNA-UHFFFAOYSA-N impromidine Chemical compound N1C=NC(CSCCNC(N)=NCCCC=2NC=NC=2)=C1C MURRAGMMNAYLNA-UHFFFAOYSA-N 0.000 description 1
- 229950005073 impromidine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003303 lafutidine Drugs 0.000 description 1
- 229950003849 lamtidine Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- ZBBBMBVEBOYSBA-UHFFFAOYSA-H magnesium;tetrapotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Mg+2].[K+].[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZBBBMBVEBOYSBA-UHFFFAOYSA-H 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- BHQQXAOBIZQEGI-UHFFFAOYSA-N methyl 2-chlorobutanoate Chemical compound CCC(Cl)C(=O)OC BHQQXAOBIZQEGI-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical group COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229950008866 mifentidine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CPQCBGMVDITBNW-UHFFFAOYSA-N n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1,1-dioxothieno[3,4-d][1,2]thiazol-3-amine Chemical compound O1C(CN(C)C)=CC=C1CSCCNC1=NS(=O)(=O)C2=CSC=C12 CPQCBGMVDITBNW-UHFFFAOYSA-N 0.000 description 1
- HIVRCMFJEMKPDS-UHFFFAOYSA-N n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-oxidopyridin-1-ium-3-carboxamide Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=C[N+]([O-])=C1 HIVRCMFJEMKPDS-UHFFFAOYSA-N 0.000 description 1
- HJZUEASXFDHGDQ-UHFFFAOYSA-N n-[3-[3-[(3-methylpiperidin-1-yl)methyl]phenoxy]propyl]-1-oxidopyridin-1-ium-3-carboxamide Chemical compound C1C(C)CCCN1CC1=CC=CC(OCCCNC(=O)C=2C=[N+]([O-])C=CC=2)=C1 HJZUEASXFDHGDQ-UHFFFAOYSA-N 0.000 description 1
- GOZUADYOHPCXLE-UHFFFAOYSA-N n-[4-(1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=CN1 GOZUADYOHPCXLE-UHFFFAOYSA-N 0.000 description 1
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- RMKWPXUWGHPLHL-UHFFFAOYSA-N octan-1-amine;dihydrochloride Chemical compound Cl.Cl.CCCCCCCCN RMKWPXUWGHPLHL-UHFFFAOYSA-N 0.000 description 1
- 229950002404 octapinol Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002908 osmium compounds Chemical class 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical group P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229940045916 polymetaphosphate Drugs 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 229950010771 ramixotidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960003320 roxatidine Drugs 0.000 description 1
- 229960003287 roxatidine acetate Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 1
- 229930190376 scutellarin Natural products 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229940077386 sodium benzenesulfonate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- 229940045919 sodium polymetaphosphate Drugs 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 1
- YKOLYTVUIVUUDY-UHFFFAOYSA-K sodium;zinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YKOLYTVUIVUUDY-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- JEYKZWRXDALMNG-UHFFFAOYSA-N sufotidine Chemical compound CN1N=C(CS(C)(=O)=O)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 JEYKZWRXDALMNG-UHFFFAOYSA-N 0.000 description 1
- 229950002504 sufotidine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 108010038851 tannase Proteins 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229950011533 tiotidine Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229950003675 zaltidine Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- GTQFPPIXGLYKCZ-UHFFFAOYSA-L zinc chlorate Chemical compound [Zn+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O GTQFPPIXGLYKCZ-UHFFFAOYSA-L 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本案主張2004年12月22日申請之美國暫時專利申請案序號第60/639,331號之優先權,其內容係完整地合併於本案以供參考。
口腔發炎與常見的口腔狀況有關,其包含例如牙周炎。牙齦炎係為齒齦疾病之初期階段。牙齦發炎的原因之一為牙斑,牙斑為形成於牙齒及齒齦上之軟質、黏性、無色的細菌膜。倘若一直未治療牙斑,則產生可能使齒齦組織發炎或感染牙齦炎之毒素。未治療的牙周炎最終將從齒齦散布至支持牙齒之韌帶和骨頭,並且能造成牙周炎。雖然許多治療係存在於用來防止及抑制口腔發炎狀況,但此等治療仍需要改善。
於許多具體例中,本發明係提供一種含有自由-B-環黃酮類化合物及黃烷之口腔組合物。再者,該組合物含有供黃酮類化合物及/或黃烷用之生物利用率增強劑。
於許多具體例中,該口腔組合物含有自由-B-環黃酮類化合物、黃烷及視需要選用口腔護理活性劑。
於某些具體例中,該口腔組合物含有自由-B-環黃酮類化合物、黃烷、供黃酮類化合物及/或黃烷用之生物利用率增強劑以及非離子型抗菌劑。
於其他具體例中,該口腔組合物含有自由-B-環黃酮類化合物、黃烷以及含有陽離子型化合物之口腔護理活性劑。
於又其他具體例中,該口腔組合物含有自由-B-環黃酮類化合物、黃烷以及含有亞錫離子源之口腔護理活性劑。
本案亦提供用以抑制及/或治療哺乳動物受試者中之口腔發炎狀況之方法。於許多具體例中,該方法包含將有效量含有自由-B-環黃酮類化合物、黃烷以及用以提高黃酮類化合物及/或黃烷於口腔之口腔組織中之生物利用率增強劑的口腔組合物施藥於受試者的口腔。
頃發現本發明之組合物及方法提供的利益包含治療口腔發炎狀況之增強的功效、抑制口腔發炎狀況之增強的功效以及減少的副作用中之一或多種。
根據本發明之口腔組合物包含一或多種自由-B-環黃酮類化合物以及一或多種黃烷。於許多具體例中,供局部(或可注射的)口服施藥用之此等組合物提供減少的口腔發炎。口腔表面及口腔組織等用語係涵蓋口腔內之硬質和軟質組織。硬質組織包含牙齒、牙周支柱等等。軟質組織包含齒齦、舌頭、口腔表面等等。
本發明提供口腔護理組合物及用於施藥、施用或應用於哺乳動物受試者(例如人類或動物)之方法。
於許多具體例中,本發明提供用以治療及/或抑制許多口腔發炎狀況(例如牙齦炎、牙周炎、口腔扁平苔蘚、舍格倫症候群(Sjögen’s syndrome)等等)之口腔組合物。口腔組合物可以許多不同形式存在。舉例來說,口腔組合物可為潔牙劑、牙膏、凝膠、粉末、漱口水、洗口藥、牙齒硬化劑、口腔薄膜、防牙菌斑組合物、薄膜、淤漿、可注射溶液或錠劑中之至少一種。
於許多具體例中,口腔組合物包含至少一種自由-B-環黃酮類化合物以及至少一種黃烷。口腔組合物較佳亦包含生物利用率增強劑。視情況可包含至少一種口腔護理活性劑。”生物利用率增強劑”代表一或多種存在於口腔組合物中之組份,係用以改良口腔護理活性化合物或其他物質施藥於口腔後變為可利用於目標組織之程度。於許多具體例中,生物利用率增強劑改良黃烷及黃酮類化合物對於目標口腔組織之利用率。生物利用率增強劑改良本發明許多具體例之口腔組合物之黃烷及黃酮類化合物二者對於口腔表面之利用率。黃烷及自由-B-環黃酮類化合物有成為親脂性之趨向,並且生物利用率增強劑增強口腔表面上之活性劑的組織攝取率及/或功效。生物利用率增強劑較佳為溶解劑與功效增強劑中之至少一種。
用於本發明中之自由-B-環黃酮類化合物及黃烷皆為一種黃酮類類型。黃酮類化合物為一類通常見於植物中之化合物,其係具有通常結構主鏈C6-C3-C6型態,並且包含諸如黃酮、黃烷、黃烷醇、異黃酮、二羥基黃烷醇、黃素酮及其衍生物等化合物。
自由-B-環黃酮類化合物構成一組黃酮類化合物,係通常於化合物之”C-環”中含有2,3-雙鍵及/或4-氧基基團(如以下之結構中所示),但通常於芳族B-環中不具取代基團。
黃烷(包含黃烷醇)具有2,3-雙鍵且通常缺少4-氧基基團(於C-環上)。常出現的黃烷醇類黃烷具有B-環羥基取代基;此等之實例包含黃烷-3’-醇及黃烷-3’,4’-二醇。自由-B-環黃酮類化合物可從許多不同的植物部位分離,此等植物部位係包含(但不限於)莖、莖皮、樹幹、幹皮、嫩枝、塊莖、根、根皮、嫩芽、組織、種子、根莖、花及其他可再生的器官、葉子及其他氣生的部位。舉例來說,於許多具體例中,自由-B-環黃酮類化合物係自美國專利申請公開案第2003/0216481號(Jia)中所述分類之植物分離。於本說明書中所引用之所有參照文獻係完整地合併於本案以供參考。
於許多具體例中,自由-B-環黃酮類化合物係分離自脣型花科植物。於許多具體例中,自由-B-環黃酮類化合物係分離自黃芩亞科植物。於許多具體例中,自由-B-環黃酮類化合物係分離自黃芩屬植物。於許多具體例中,自由-B-環黃酮類化合物係分離自黃芩種植物。中藥植物黃芩含有大量自由-B-環黃酮類化合物,係包含黃芩素、黃芩苷、漢黃芩素以及黃芩素糖苷。含有自由-B-環黃酮類化合物之成分已顯示尤其可抑制環氧化酶酵素COX-2之活性。
黃烷係為可自不同植物部位分離之黃酮類化合物,此等植物部位係包含(但不限於)莖、莖皮、樹幹、幹皮、嫩枝、塊莖、根、根皮、嫩芽、組織、種子、根莖、花及其他可再生的器官、葉子及其他氣生的部位。於許多具體例中,可自美國專利申請公開案第2003/0216481號(Jia)中所述分類之植物分離黃烷。於許多具體例中,可自豆科植物分離黃烷。於許多具體例中,可自含羞草亞科植物分離黃烷。於許多具體例中,可自金合歡族植物分離黃烷。於許多具體例中,可自金合歡屬分離黃烷。於許多具體例中,可自兒茶分離黃烷。
兒茶素係為於廣泛地發現於金合歡中之黃烷。兒茶素(單獨地或合併茶中發現的黃酮類化合物二者)係展現抗病毒及抗氧化活性。兒茶素亦展現可抑制COX-1和COX-2酵素二者之活性。
藉使用技藝中熟知的任一種適合的萃取技術,可自以上植物的組織萃取自由-B-環黃酮類化合物。舉例來說,可用的萃取技術係為任一種適合的水性萃取或有機溶劑萃取作用。較佳的萃取技術使用水、甲醇、水/甲醇、二氯甲醇及甲醇:THF。可使用任一種其他適合的萃取技術,例如蒸氣蒸餾、超臨界液體萃取及美國專利申請公開案第2003/0216481號(Jia)中所述之任一種技術。
基於不同因素(例如欲治療的特定狀態),可調整口腔組合物中之自由-B-環黃酮類化合物對黃烷的比例。於許多應用中,自由-B-環黃酮類化合物對黃烷的比例可於約99:1自由-B-環黃酮類化合物:黃烷至約1:99自由-B-環黃酮類化合物:黃烷。自由-B-環黃酮類化合物對黃烷的比例可選自由約90:10、80:20、70:30、60:40、50:50、40:60、30:70、20:80及10:90所組成之群。於許多具體例中,自由-B-環黃酮類化合物對黃烷的比例為約85:15。可使用許多不同的技術來產生至少一種自由-B-環黃酮類化合物與至少一種黃烷之混合物。此混合物之特殊製備例係提供於美國專利申請公開案第2003/0216481號(Jia)。
至少一種自由-B-環黃酮類化合物與至少一種黃烷之混合物可以許多不同含量存在於本發明的組合物中。於許多具體例中,混合物存在於口腔組合物中之含量可為超過約0.001重量%,約0.001重量%至約5重量%,約0.01重量%至5重量%,約0.1重量%至約3重量%,約0.1重量%至約1重量%,或約0.1重量%至約0.5重量%。
至少一種自由-B-環黃酮類化合物與至少一種黃烷可合併形成適用於根據本發明組合物中之混合物。同樣地,含有至少一種自由-B-環黃酮類化合物之植物提取物可合併含有至少一種黃烷之植物提取物,俾形成此中所用之混合物。此等混合物亦於市面上有售。一種實例為UNIVERSTIN,其係由美國科羅拉多州之Unigen Pharmaceuticals,Inc.,Superior所製造和出售。UNIVERSTIN之完整說明可見於美國專利申請公開案第2003/0216481號(Jia)。咸信UNIVERSTIN可抑制催化口腔發炎途徑之特殊酵素(COX-1、COX-2及5-LO酵素)。於許多具體例中,自由-B-環UNIVERSTIN黃酮類化合物係自黃芩屬植物組織分離。適用於製備至少一種自由-B-環黃酮類化合物與至少一種黃烷之混合物之方法係提供於美國專利申請公開案第2003/0216481號(Jia),例如於實施例14。
於一具體例,至少一種自由-B-環黃酮類化合物與至少一種黃烷之混合物含有至少約80至約90重量%之活性成分化合物,更特別地為約86%活性化合物,其中76重量%為自由-B-環黃酮類化合物且約10%為黃烷。於此混合物中,咸信自由-B-環黃酮類化合物含有:黃芩苷(約63%)、漢黃芩素-7-葡萄醣醛苷(約7%)、木蝴蝶素A-7-葡萄醣醛苷(約2%)、黃芩素(小於約2%)、漢黃芩素(約1%)、白楊素-7-葡萄醣醛苷(約1%)、5-甲基-漢黃芩素-7-葡萄醣醛苷(約0.5%)、野黃芩苷(小於約0.5%)、新漢黃芩素(小於約0.5%)、白楊素(小於約0.2%)以及木蝴蝶素A(小於約0.2%)。咸信黃烷包含:兒茶素(約10%)及表兒茶素(小於約0.5%)。
於某些具體例中,生物利用率增強劑包含適用於提高黃酮類化合物及/或黃烷於口腔組合物中的溶解度之溶解劑,其係於口腔組合物含有親水性或水性載體時特別有利。於一具體例中,生物利用率增強劑含有功效增強劑,其係改良或增強口腔護理活性化合物對於目標組織產生所需效果之能力。於某些具體例中,生物利用率增強劑包含功效增強劑,該功效增強劑係為含有增強傳送黃酮類化合物及/或黃烷(及視需要選用口腔護理活性劑)至口腔組織之傳送增強基團以及提高口腔組織對黃酮類化合物及/或黃烷(及視需要選用口腔護理活性劑)的保留率之保留增強基團。生物利用率增強劑視情況含有功效增強劑與溶解劑二者。
此中所用之傳送增強基團代表生物利用率增強劑上的部分(當其為功效增強劑時),係貼附或實質上、黏附上、黏著地或者連接載有自由-B-環黃酮類化合物/黃烷混合物(及視需要選用口腔護理活性劑)之功效增強劑於口腔(例如牙齒及齒齦)表面,藉以”傳送”成分及視需要選用的活性護理劑於口腔表面。保留增強基團(通常為疏水性的)係貼附或者連接自由-B-環黃酮類化合物/黃烷混合物及視需要選用口腔護理劑(尤其於其為非離子型時)於功效增強劑,藉以促進此等化合物直接地保留於功效增強劑上且間接地保留於口腔表面上。於一些情況下,自由-B-環黃酮類化合物/黃烷混合物及視需要選用口腔護理劑之貼附作用係透過受到功效增強劑的物理性纏繞而出現,尤其是當功效增強劑為交聯聚合物且其結構固有地提高增加的貼附區時。於交聯聚合物中之較高分子量、更具疏水性的交聯部分之存在仍進一步促進自由-B-環黃酮類化合物、黃烷及視需要選用口腔護理劑於交聯的功效增強劑聚合物之中或之上的物理性纏繞作用。
於某些具體例中,生物利用率增強劑含有功效增強劑,該功效增強劑係含有具有傳送增強基團和保留增強基團之水溶性或可溶脹的陰離子型聚合物或共聚合物,其中傳送增強基團增強傳送自由-B-環黃酮類化合物、黃烷及/或口腔護理劑至受試者的口腔組織,並且保留增強基團增強口腔組織對自由-B-環黃酮類化合物、黃烷及/或口腔護理劑之保留率。
功效增強劑亦可包含特徵在於具有作為齒列黏著劑或固定劑或牙科補泥應用者。功效增強劑係為聚合物或共聚合物,該術語是一般性的,因此包含例如寡聚物、均聚物、二或多種單體之共聚物、離子聚合物、嵌段共聚物、接枝共聚物、交聯聚合物及共聚物以及類似物。其可為天然或合成的以及水(唾液)可溶或可溶脹的(可水合、形成凝膠的)聚合物或共聚物。
倘若功效增強劑包含傳送增強基團,則其可為美國專利第5,538,715及5,776,435號(二者皆屬Gaffar等人)中所列之任一種。於許多具體例中,傳送增強基團較佳為酸性的,例如磺酸系、次膦酸系,或更佳為膦酸系或羧酸系,或其鹽類(例如鹼金屬或銨鹽)。當存在時,保留增強基團可為任一種有機保留增強基團,例如具有式-(X)n
-R者,其中X為O、N、S、SO、SO2
、P、PO或Si或類似物,R為疏水性烷基、烯基、醯基、芳基、烷芳基、芳烷基、雜環或其惰性取代的衍生物,並且n為0或1或更大。”惰性取代的衍生物”一詞係包含R上的取代基,其通常為非親水性的,並且不會明顯地干擾功效增強劑用以增進傳送及保留口腔組合物活性劑(包含黃酮類化合物、黃烷及視需要選用口腔護理活性劑)於口腔表面之所需的功能,例如鹵素,例如Cl、Br、I及羧基等等。
可選擇具有不同大小之功效增強劑。舉例來說,於功效增強劑含有合成陰離子聚合或線型陰離子聚合的聚羧酸酯之具體例中,其可具有平均M.W.為約100至約5,000,000、1,000至約3,000,000、1,000,000至約3,000,000,並且於口腔組合物中之存在量為約0.0005至約5重量%,約0.005至約4重量%,或約0.05至約3重量%。較佳的共聚物為馬來酸酐或馬來酸與其他可聚合的乙烯系不飽和單體(較佳為甲基乙烯基(甲氧基乙烯),通常稱為PVM/MA)之1:4至4:1共聚物。此等共聚物之實例係以商品名GANTREZ售自ISP Corporation,例如AN 139(M.W.1,100,000)、AN 119(M.W.200,000)、S-97醫藥級(M.W.1,500,000)以及AN 179(M.W.2,400,000);其中較佳的共聚物為S-97醫藥級(M.W.1,500,000)。
功效增強劑的傳送增強基團亦可為不同的膦酸酯/鹽。此等膦酸鹽型功效增強劑可具有平均M.W.為約100至約1,000,000或約1,000至約1,000,000。功效增強劑可為M.W.為約1000或更多之聚乙烯基膦酸酯及/或鹼金屬聚乙烯基膦酸鹽及/或聚乙烯基膦酸銨。膦酸酯/鹽型功效增強劑於口腔組合物中之存在量可為約0.0005至約4重量%。功效增強劑可為聚(β-苯乙烯膦酸酯)、聚(α-苯乙烯膦酸酯)、共聚(α,β-苯乙烯膦酸酯)或α-苯乙烯膦酸酯或β-苯乙烯膦酸酯與其他可聚合的乙烯系不飽和單體之其他共聚物,例如共聚(β-苯乙烯膦酸酯/乙烯基膦酸酯)。膦酸酯/鹽型功效增強劑可具有M.W.為約2,000至約30,000。於許多具體例中,功效增強劑於口腔組合物中之存在量可為約0.0005至約5重量%。
口腔組合物包含生物利用率增強劑,其可以且較佳亦包含一或多種溶解劑,俾溶解至少一種自由-B-環黃酮類化合物與至少一種黃烷之混合物。於某些具體例中,溶解劑易溶解一或多種口腔護理劑,尤其是於化合物為非離子型或親脂性時。溶解劑可為任一種有效於溶解至少一種自由-B-環黃酮類化合物與至少一種黃烷之混合物之溶解劑。舉例來說,於許多具體例中,溶解劑可含有一或多種以下物質:酯類、酮類、二醇類(聚乙二醇(PEG)和甲基化的PEG二者)、油脂、油類、脂肪、吡咯烷酮以及聚吡咯烷酮。溶解劑可進一步包含二甲基亞碸(DMSO)、二甲基甲醯胺(DMF)、N-甲基吡咯烷酮以及其他極性非質子溶劑(例如具有介電常數大於30之極性非質子溶劑)。再者,溶解劑可包含口部可接受的表面活性劑,例如界面活性劑、調味油、醇及溶解性濕潤劑(例如丙二醇)。
可用的界面活性劑之實例包含陰離子型、非離子型、兩性、兩性離子型及陽離子型合成洗潔劑。陰離子型界面活性劑包含於烷基基團具有8至20個碳原子之硫酸烷酯的水溶性鹽類(例如烷基硫酸鈉)、具有6至18個碳原子之磷酸單烷酯、具有8至20個碳原子之脂肪酸的磺酸化單甘油酯的水溶性鹽類(例如月桂基硫酸鈉(純度>82%)及椰子單甘油酯磺酸鈉)以及烷基糖苷(為單[烷基(C1 2
-C2 2
)]-[(Glyc)1 - 2 0
])、肌胺酸鹽(例如月桂醯基肌胺酸、肉豆蔻醯基肌胺酸、棕櫚醯基肌胺酸、硬脂醯基肌胺酸及油醯基肌胺酸的鈉和鉀鹽)、異硫代酸鹽(例如月桂醯基異硫代酸鈉)、月桂醇聚氧乙烯醚羧酸鈉、十二基苯磺酸鈉以及上述物質之混合物。較佳者為肌胺酸鹽,因為其可抑制口中因碳水化合物分解而生之酸形成。
非離子型界面活性劑包含泊洛沙姆(poloxamer)(以商品名PLURONIC出售);聚氧伸乙基山梨聚糖酯(以商品名TWEEN出售);脂肪醇乙氧基化物;烷基酚之聚氧化乙烯縮合物;衍生自氧化乙烯與脂肪酸、脂肪醇、脂肪醯胺或多元醇的縮合物之產物;以及脂肪醇的聚氧化丙烯或氧化乙烯縮合物;長鏈三級胺氧化物;長鏈三級膦氧化物;長鏈二烷基亞碸;以及此等材料之混合物。兩性界面活性劑包含甜菜鹼(例如柯卡醯胺基丙基甜菜鹼)、脂族二級胺和三級胺的衍生物,其中脂族基團可為直鏈或分支鏈,並且其中脂族取代基之一含有約8至18個碳原子,並且之一含有陰離子型水溶解基團(例如羧酸根、磺酸根、硫酸根、磷酸根或膦酸根)。
兩性離子界面活性劑包含脂族銨、鏻及鋶化合物,其中脂族基團可為直鏈或分支鏈,並且其中脂族取代基之一含有約8至18個碳原子,並且之一含有陰離子型水溶解基團(例如羧基、磺酸根、硫酸根、磷酸根或膦酸根)。
陽離子型界面活性劑包含具有一個含有約8至18個碳原子長鏈之脂族四級銨化合物(例如氯化月桂基三甲基銨、氯化十六基吡錠、溴化十六基三甲基銨、氯化二異丁基苯氧基二甲基苄基銨、亞硝酸椰油烷基三甲基銨、氟化十六基吡錠)。某些陽離子型界面活性劑亦可充當抗菌劑。
口腔組合物亦可含有濕潤劑多元醇及酯類,俾輔助溶解自由-B-環黃酮類化合物和黃烷(視需要選用一種口腔護理劑)之混合物,俾容許傳送至齒齦處或接近齒齦之軟質口腔組織。可使用任一種適合的濕潤劑多元醇及酯類,例如一或多種以下物質:丙二醇、一縮二丙二醇及己二醇;溶纖劑,例如甲基溶纖劑及乙基溶纖劑;於直鏈中含有至少約12個碳原子之植物油脂及蠟,例如橄欖油、蓖麻油及三硬脂酸甘油酯;以及酯類,例如醋酸戊酯、醋酸乙酯以及苯甲酸苄酯。亦可使用礦脂以及甘油、山梨醇及/或木糖醇。丙二醇為較佳。此中所用之”丙二醇”一詞包含1,2-丙二醇及1,3-丙二醇。丙二醇可以任一適當含量存在,例如足以溶解抗菌劑及/或自由-B-環黃酮類化合物/黃烷之混合物,並且防止當以唾液稀釋時沉澱之含量。
任一種適合的調味料或增甜材料亦可用作溶解劑,以及增進口腔組合物之美味。適合的調味組份的實例為調味油,例如綠薄荷、薄荷、冬青、黃樟、丁香、鼠尾草、桉樹、墨角蘭、肉桂、檸檬、柳橙及水楊酸甲酯之油脂。適合的增甜劑包含蔗糖、乳糖、麥芽糖、木糖醇、環磺酸鈉、蔗糖素、紫蘇葶(perillartine)、AMP(天門冬胺醯基苯基丙胺酸,甲基酯)、糖精及類似物。咸信調味油係輔助溶解某些非離子性活性劑化合物。亦可使用含有桉樹酚、百里香酚、水楊酸甲酯及甲醇之酚系調味劑混合物。
調味及/或增甜材料可以任一適合含量存在。於許多具體例中,調味及/或增甜材料之存在量係足以溶解自由-B-環黃酮類化合物、黃烷及視需要選用活性劑之混合物,並且防止當以唾液稀釋時沉澱。於許多具體例中,調味材料之存在量可為生物利用率增強劑(係為供自由-B-環黃酮類化合物/黃烷混合物用之溶解劑)重量之約0.5%至約50%,並且其含量係足以溶解自由-B-環黃酮類化合物/黃烷混合物於唾液中。於許多其他具體例中,調味及/或增甜材料之存在量係足以提高口腔組織對自由-B-環黃酮類化合物/黃烷混合物的攝取率。因此,於某些具體例中,調味及/或增甜劑之每一者或一起佔口腔組合物之約0.001至約5%。於某些具體例中,於口腔護理劑含有非離子型抗菌劑時,調味劑之存在量可為酚系調味混合物之約0.02至約2%,此含量使得實質上水不溶性非陽離子抗菌劑:酚系調味劑之比例為5:1至1:100。
溶解劑可以不同含量存在於口腔組合物中,例如含量係足以溶解自由-B-環黃酮類化合物及黃烷之混合物,並且防止當以唾液稀釋時沉澱。溶解劑亦可以有效於提高口腔組織對抗菌劑及自由-B-環黃酮類化合物和黃烷之混合物的攝取率之含量存在。溶解劑較佳係以約0.02至50重量%存在。
於許多具體例中,口腔組合物視情況含有一或多種口腔護理劑。於某些具體例中,口腔護理劑係選自由以下物質所組成之群:抗菌劑、抗微生物劑、抗齲劑、抗牙垢劑、抗附著劑、生物膜分解劑、抗發炎劑(除了自由-B-環黃酮類化合物及黃烷外)、抗生素及其混合物。熟習本技藝之人士當可明白,口腔護理活性化合物或活性劑可屬於此等分類之一或多種,因為其可具有多重機制及/或效果,並且不應視為以單一功能或分類為限。於某些具體例中,口腔護理活性化合物具有防止及/或治療口腔護理疾病之官能性或機制,其中機制係補足及/或補充如上述由自由-B-環黃酮類化合物及黃烷所提供之機制。
口腔組合物視情況含有有效抗牙斑及/或抗牙齦炎量之一或多種口腔護理劑。可使用任一種適合的抗菌或抗牙斑口腔護理劑。於此中所用之口腔護理劑中,口部可接受的口腔護理劑包含非離子型抗菌劑、陽離子型抗菌劑、陽離子型活性化合物及陰離子型抗菌劑。
於某些具體例中,口腔護理劑為可含有不同的酚系化合物之非離子型抗菌劑,酚系化合物包含酚類及其同系物、單烷基-及多烷基-及芳族鹵基-(例如氟、氯、溴、碘)酚、間苯二酚及兒茶酚以及其衍生物及雙酚系化合物。此等化合物包含:
間苯二酚及其衍生物
有效的口服護理抗菌劑之其他例示系列係提供於美國專利第5,776,435號(Gaffar等人)、第5,681,548號(Esposito等人)、第5,912,274及5,723,500號(二者皆屬Stringer等人)。
於許多具體例中,非離子型抗菌劑含有酚系及/或雙酚系化合物,例如鹵化的二苯醚(包含三氯生(triclosan,2,4,4’-三氯-2-羥基-二苯醚)、三氯卡班(triclocarban,3,4,4-三氯碳醯替苯胺)、2-苯氧基乙醇、苯甲酸酯、碳醯替苯胺、酚類、麝香草酚、丁子香酚、己基間苯二酚及2,2’-亞甲基雙(4-氯-6-溴酚)。此等抗菌劑可以不同含量存在,例如約0.001重量%至約5重量%。
於一些具體例中,抗菌劑可為如美國專利第5,292,526號(Gaffar等人)中所討論之實質上不溶於水之非離子型抗菌劑。於某些具體例中,非離子型抗菌劑包含鹵化的二苯醚,較佳為2’,4,4’-三氯-2-羥基-二苯醚(三氯生)。三氯生可以不同含量存在於口腔組合物中,例如含量為口腔組合物之約0.01重量%至約5重量%或約0.25重量%至約0.35重量%。
口腔護理劑亦可視情況含有陽離子型抗菌劑。適用於口腔組合物中之適合的陽離子型抗菌劑包含例如:(i)四級銨化合物,例如其中四級氮上之一或多個取代基具有8至20(較佳為10至18個)碳原子且較佳為烷基(視情況插入醯胺、酯、氧、硫或雜環狀環),而剩餘的取代基具有較低數目的碳原子(例如1至8)且較佳為烷基(例如甲基或乙基或苄基)之四級銨化合物。此等化合物之實例包含氯化苄烷銨、十二基三甲基氯化銨、苄基二甲基硬脂基氯化銨、十六基三甲基溴化銨、苄索氯銨(benzethonium chloride)(二異丁基苯氧基乙氧基乙基二甲基苄基氯化銨)及甲基苄索氯銨;(ii)吡錠及異喹啉鎓化合物,包含氯化十六基吡錠、溴化烷基異喹啉鎓、氯化十四基吡錠及氯化N-十四基-4-乙基吡錠;(iii)嘧啶衍生物,例如海克替啶(hexetidine)(5-胺基-1,3-雙(2-乙基己基)-5-甲基-六氫嘧啶);(iv)脒,己烷脒(hexamidine isothionate)(4,4’-胺基-α,ω-二苯氧基-己烷脒);(v)雙吡啶衍生物,例如奧替尼啶(octenidine)二鹽酸鹽(N’N’-[1,10-癸烷二基二-1(4H)-吡啶-4-亞基]-雙(1-辛烷胺二鹽酸鹽));(vi)胍類,例如單-雙胍類,例如對-氯苄基-雙胍及N’-(4-氯苄基)-N”-(2,4-二氯苄基)雙胍;聚(雙胍類),例如聚六亞甲基雙胍鹽酸鹽以及通式(1)之雙-雙胍類:
(vii)其中A及A’每一者代表(i)苯基基團,視情況以(C1 - 4
)烷基、(C1 - 4
)烷氧基、硝基或鹵素取代,(ii)(C1 - 1 2
)烷基基團,或(iii)(C4 - 1 2
)非環狀基團;X及X1
每一者代表(C1 - 3
)伸烷基;R及R1
每一者代表氫、(C1 - 1 2
)烷基或芳基(C1 - 1 2
)烷基;Z及Z1每一者係為0或1;n為整數2至12;並且聚亞甲基鏈(CH2
)n
可視情況插入氧或硫或芳族(例如苯基或萘基)核;以及口部可接受的酸加成鹽類;此等雙-雙胍類之實例包含氯已定(chlorhexidine)及阿來西定(alexidine)。適合的通式(1)之雙-雙胍類的酸加成鹽類包含二醋酸鹽、二鹽酸鹽及二葡萄糖酸鹽。氯已定之適合的酸加成鹽類包含二葡萄糖酸鹽、二甲酸鹽、二醋酸鹽、二丙酸鹽、二鹽酸鹽、二氫碘酸鹽、二乳酸鹽、二硝酸鹽、硫酸鹽及酒石酸鹽。阿來西定之適合的酸加成鹽類包含二氫氟酸鹽及二鹽酸鹽;以及其他視需要選用之陽離子型化合物之口腔護理劑,其包含一般以以下式(2)表示之Nα
-醯基胺基酸烷基酯及鹽類:
其中R1
為1至8個碳原子(較佳為1至3個碳原子,最佳為3個碳原子)之烷基鏈;R2
為6至30個碳原子(較佳為10至12個碳原子)之烷基鏈,以及其混合物;且X為陰離子。於許多具體例中,R2
CO部分包含天然脂肪酸殘基,例如選自由椰油脂肪酸、牛油脂肪酸殘基組成之群之天然脂肪酸,或單脂肪酸殘基,例如選自由月桂醯基(C1 2
)、肉豆蔻基(C1 4
)、硬脂醯基(C1 8
)及其混合物。於某些具體例中,R2
CO部分包含月桂醯基脂肪酸殘基。
X可為提供合理的水中溶解度(較佳為約1克/於1升水中)之任一種抗衡陰離子。形成上式酯鹽類之X抗衡陰離子的實例包含無機酸鹽,例如含有鹵原子(例如氯或溴)者或磷酸二氫鹽,或有機鹽類,例如醋酸鹽、酒石酸鹽、檸檬酸鹽或吡咯烷酮-羧酸酯(PCA)。氯鹽為較佳。
適用於本發明口腔組合物之上述酯類的實例(其中於式中之n等於3)包含Nα
-椰油基-L-精胺酸甲基酯、Nα
-椰油基-L-精胺酸乙基酯、Nα
-椰油基-L-精胺酸丙基酯、Nα
-硬脂醯基-L-精胺酸甲基酯、Nα
-硬脂醯基-L-精胺酸乙基酯鹽類(例如鹽酸鹽)。於一具體例中,陽離子型口腔藥劑包含乙基月桂醯基精胺酸(ELAH)之鹽酸鹽。
因此,於某些具體例中,較佳的陽離子型活性劑係選自由苄索氯銨(benzethonium chloride)、奧替尼啶(octenidine)、海克替啶(hexetidine)、己咪定(hexamidine)、氯化十六基吡錠、氯已定(chlorhexidine)、阿來西定(alexidine)、Nα
-醯基胺基酸烷基酯鹽類及其混合物所組成之群。於某些具體例中,陽離子型口腔護理劑包含氯化十六基吡錠(CPC)。於某些具體例中,口腔護理劑包含Nα
-醯基胺基酸烷基酯鹽類,例如乙基月桂醯基精胺酸(ELAH)。
於其他具體例中,口腔護理活性劑係為抗附著劑。雖然不欲限制本發明,但咸信口腔護理活性成分通常受兩種主要抗黏著機制之任一者(或二者)作用。生物膜(亦稱為薄膜)係為形成於口腔表面上(通常於硬質組織表面上)之基質,係包含細菌(通常為生物基質之約60-70%)、細菌胞外副產物、蛋白質、脂質及糖脂類。
生物膜之早期形成階段包含黏著初細菌層於口腔表面上(咸信通常係透過與口腔表面上之受體產生交互作用之配基或細菌細胞壁之黏附力而黏接)。咸信細菌細胞係黏附於口腔表面(例如琺瑯質)上之唾液糖蛋白。細菌接著生長及分裂形成口腔表面上之緻密層。於達到特定密度之後,咸信許多菌種黏附於細菌的錨定層,以形成生物膜基質。
因此,抗附著劑可與口腔表面產生交互作用,使得細菌及生物膜成分可黏附於口腔表面,並且無錨定層可形成於口腔表面上。此一抗附著劑實質上覆蓋於口腔表面上,並且防止細菌及生物膜之其他成分黏著。第二種機制為其中抗附著劑與細菌本身產生交互作用,使其失去黏著於口腔表面之能力(同樣地藉由與細菌表面上一般可促進受體或其他於口腔表面連接之黏附素、配基或其他部分產生交互作用)。
雖然不欲限制本發明,但咸信於某些具體例中,上述的Nα
-醯基胺基酸烷基酯鹽類,例如乙基月桂醯基精胺酸(ELAH)係發揮抗黏著活性成分之功能。酸然不欲限制此等口腔護理劑之運作機制,但咸信ELAH似乎改變牙齒表面能量(降低),進而防止可於牙齒表面上形成牙菌斑生物膜微生物之黏附及黏著。ELAH似乎對牙齒表面有直染性,使得其保持黏附一段足夠的期間,俾有效地防止微生物黏附於牙齒表面,藉以防止或降低生物膜形成。
根據本發明之許多具體例,相較於許多在水性口腔中洗掉之抗菌成分,應用ELAH作為活性劑係以較低濃度促進較長及較有效的抗牙菌斑效益。
於一些具體例中,口腔護理劑包含為生物膜分解劑之口腔護理活性劑。生物膜分解劑通常為可防止形成及/或侵襲已形成於口腔表面上之生物膜(或薄膜)。
基於水解蛋白質、澱粉與脂質(係形成一部分生物膜)的能力,酵素通常已選用為生物膜分解劑。於某些具體例中,此等酵素透過實例包含例如蛋白酶酵素,例如半胱胺酸蛋白酶或絲胺酸蛋白酶。實例係最合宜地選自以下物質所組成之群:木瓜酶(例如分離自木瓜的綠色果實的乳膠及葉子)、無花果蛋白酶(例如分離自熱帶無花果樹Ficus glabrata之乳膠)、南極蝦酶(例如分離自南極蝦)、其他半胱胺酸蛋白質酶及絲胺酸蛋白質酶、糖化酶(glycoamylase)、葡萄聚糖分解酶、突變酶(mutanase)、溶菌酶、植物脂肪酶、胃脂肪酶、胰脂肪酶、鞣酸酶、菠蘿蛋白酶、糜蛋白酶、鹼性蛋白酶、澱粉酶、乳鐵蛋白酶、牙齦單胞菌酶、葡萄糖氧化酶、彈性酶及/或纖維素酶以及其混合物。供口腔用之其他例示的生物膜分解劑包含合成組胺酸蛋白酶、呋喃酮、呋喃酮的衍生物以其上述任一物質之混合物。
除了上述物質外,本發明之口腔組合物可視情況抗牙斑分解劑,其係包含(但不限於):銅、鎂及鍶鹽;二甲矽油共聚醇類,例如十六基共聚醇、尿素、乳酸鈣、甘油磷酸鈣、聚丙烯酸鍶以及其混合物。
於某些具體例中,口腔護理劑包含為抗發炎劑之口腔護理活性劑。口腔組織之發炎通常反映出因組織損傷或破壞所引起之局部防護回應,其係用以破壞、稀釋或隔離有害藥劑及損傷組織二者。慢性發炎通常為急性發炎之持續,並且為延長的低階發炎形式(例如與牙周炎或牙齦炎有關),並且造成永久性組織損壞。於歷史上,發炎涉及複雜的事件系列,並且對應於提高含量的後發炎性細胞中介物(自細胞釋放者),故造成抗原與抗體之交互作用或抗原與敏感性淋巴球之作用。
一或多種上述後發炎性細胞中介物之抑制可預防及/或治療涉及口腔疾病之組織損壞及/或組織損失。因此,含有額外抗發炎劑(除了自由-B-環黃酮類化合物及黃烷外)以抑制一或多種發炎中介物之口腔組合物係用於本發明之某些具體例中。抗發炎劑亦可抑制免疫系統識別一或多種由口腔中病原體產生之抗原。舉例來說,革蘭氏陰性菌具有內毒素,通常已知為脂多醣(LPS)成分,其係為由免疫系統中之許多細胞所偵測到之抗原,俾產生免疫系統回應(包含產生發炎性中介物及活化串級補充及凝集串級)。根據本發明之某些有用的抗發炎化合物可防止受試者的免疫系統免於識別或回應一或多種存在於口腔中之抗原,例如革蘭氏陰性菌之細胞壁上的LPS。咸信透過有效地掩飾受到免疫系統偵測或防止免疫系統回應(經由抑制因應識別LPS所產生之細胞間中介物,藉以抑制免疫系統回應),此等抗發炎藥物與抗原依照微生物/細菌/抗原不再被免疫系統之某些細胞的受體識別之方式干擾。舉例來說,咸信LPS觸發免疫系統事件之複雜串級,其包含活化及釋放NF-B(核因子B)。咸信NF-B觸發免疫回應,包含骨質溶解症及骨髓炎(例如因應口腔中細菌所產生之LPS)。調整或預防NF-B產生之化合物係用於本發明。此等實例包含歐甘菊類,例如倍半萜烯內酯歐甘菊(咸信其係抑制PLS所誘發之骨質溶解症)。此等活性劑化合物之其他非限定實例包含雄烯二醇(AED)及脫氫表雄甾酮(DHEA)。本發明進一步涵蓋其他已發現或將發現之此類活性化合物。
其他有效的抗發炎劑可包含預防發炎中介物累積者,例如衍生自花生四烯酸途徑者,其係經由抗原之免疫系統偵測而觸發。一種調整發炎回應之中介物係為花生四烯酸代謝物,即前列腺素、白三烯及血栓素(係透過環氧化酶或脂氧化酶酵素途徑產生)。此等代謝物已意味著為牙齦炎、牙周炎、骨髓炎及其他發炎疾病中之主要中介物。透過實例,此等防止發炎性中介物自花生四烯酸途徑累積之抗發炎劑包含例如非類固醇類抗炎藥(NSAIDs)。有效的NSAID抗發炎劑包含選自由以下物質組成之群者:吲哚美辛(indomethicin)、氟比洛芬(flurbiprofen)、酮洛芬(ketoprofen)、布洛芬(ibuprofen)、萘普生(naproxen)、甲氯胺苯酸(meclofenamic acid)以及其混合物。
同樣地,另一種供口腔護理抗發炎劑用之機制係為其中抗發炎劑適用於降低或清除口腔中之一或多種反應性氧化物物質者。反應性氧化物物質(ROS)係為於許多的生化程序過程中生成之典型的高反應性產物,並且包含超氧化物陰離子(O2 -
)、過氧化氫(H2
O2
)以及羥基基團(.OH)。ROS之形成可發生為許多細胞程序之部分,係包含免疫細胞回應及細胞損傷。咸信於病態條件下增加ROS之形成,係經由此等高活性分子經由交聯蛋白質、使DNA突變及使脂質過氧化,而造成細胞損壞。雖然不欲受限於本發明之任一理論,但通常咸信至少一種自由-B-環黃酮類化合物及黃烷操作之一種機制係為經由降低一或多種口腔中之ROS(除了抑制催化口腔發炎路徑之特殊酵素外,例如COX-1、COX-2及5-LO酵素)。
其他適用於口腔護理劑之適合的抗發炎劑包含例如2005年10月24日申請之美國專利申請案序號第11/256,788號(Worrell等人)所揭示之牛至提取物(例如來自牛至(通常稱為”oregano”、”wild oregano”或”wild marjoram”)之提取物),或2005年11月23日申請之美國專利申請案序號第11/285,809號(Gaffar等人)所揭示之木蘭提取物(係衍生自木蘭料中之植物,例如厚朴)。
視需要選用之例示的抗氧化劑為丁基化的羥基茴香醚(BHA)、丁基化的羥基甲苯(BHT)、維生素A、類胡蘿蔔素、生育酚(維生素E)、草本抗氧化劑、葉綠素、褪黑激素、氯化物、鈣、氧化鈣、氮化鈣、泛醌二鈉(disodium ubiquinone)(輔酶Q1 0
)、沒食子酸乙基己酯、過氧化氫、碘、茄紅素、抗壞血酸鎂、亞硫酸鉀、重亞硫酸鈉、硫代乳酸以及其混合物。
於某些具體例中,口腔組合物包含為抗生素之口腔護理活性劑,例如安美汀(augmentin)、阿莫西林(amocillin)、四環黴素、去氧羥四環黴素、新黴素(neomycin)、甲硝唑(metronidazole)、卡那黴素(kanamycin)及克林達黴素(clindamycin)以及其混合物。
其他可包含於口腔組合物中作為活性成分之視需要選用的口腔護理化合物包含例如未於以上討論之額外的抗菌劑、潔白劑、未於以上討論之額外的抗齲劑及牙垢控制劑、牙周活性劑、呼吸清新劑、惡臭控制劑、牙齒減敏劑、唾液興奮劑、潔白劑、止痛劑以及其組合。應瞭解雖然以上活性劑種類之每一者的一般特性可以不同,但是可有一些共同特性,並且任一種給定的材料可符合二或多種此等活性劑種類範圍內之多重目的。
此中有效的例示活性劑係揭示於美國專利第4,894,220號(Nabi等人)、第5,288,480號(Gaffar等人)、美國專利申請公開案第2003/0206874號(Doyle等人)以及美國專利第6,290,933號(Durga等人)及美國專利第6,685,921號(Lawlor)。此等活性成分係熟習本技藝之人士所知曉。此等活性劑較佳係選擇可與自由-B-環黃酮類化合物/黃烷混合物相容者。本發明涵蓋口腔混合物之其他混合物(甚至在相同分類範圍內亦同)。
此中有效的活性口腔護理劑係以安全和有效量視情況存在於本發明之組合物中。”安全和有效”含量係為足以於施加活性劑於人類或低等動物受試者中具有所需療效或預防疾病效果,而不會有不當的副作用(例如毒性、刺激或過敏性回應)之含量,當依照本發明使用時,其係與合理的利益/風險比值相當。活性劑的特殊安全和有效含量將隨著諸如特定的治療條件、受試者的身體狀態、協力治療(若有的話)、所用之特殊活性劑、特殊劑型、所用之載體以及所需的劑量食物療法等因素而改變。除非特別指明,否則口腔護理劑可以含量為口腔組合物之約0.001至約5重量%存在於口腔護理組合物中。
任一種適合的氟離子源可存在口腔組合物中,例如揭示於美國專利第5,080,887號(Gaffar等人)中者。氟離子源可為稍微或完全水溶性的,並且通常具有抗齲功能。氟離子源(或任一種離子源)的特徵在於其於水中釋放氟離子之能力,以及沒有與口腔組合物之其他化合物產生不想要的反應。可存在有一或多種此等離子源。此等離子源的實例為無機金屬及/或氟化銨鹽以及諸如氟化鈉、氟化鉀、氟化銨、氟化鈣、氟化亞銅、氟化鋅、氟化鋇、矽氟化鈉、氟矽酸銨、氟鋯酸鈉、單氟磷酸鈉、氟化亞錫、單氟磷酸銨、二氟磷酸銨以及氟化的焦磷酸鈉鈣。氟離子源亦可為氟化胺,例如olaflur(N’-十八基三亞甲基二胺-N,N,N’-三(2-乙醇)-二氟化氫鹽)。於一些具體例中,氟化鈉或單氟磷酸鈉為較佳。
氟離子提供來源之含量係於某種程度上取決於來源的類型、其溶解度以及口腔組合物的形式,但通常將以約0.001%至約3.0%之無毒性含量存在於口腔組合物中。於牙膏組合物中(例如牙膠、牙膏(包含乳膏)、牙粉或牙科用錠),釋放製劑重量之至多5,000 ppm之F-離子之此等來源的含量被認為是令人感到滿意的。可使用任一種適合的最小含量之此等來源,但較佳係使用含量足以釋放約300至2,000 ppm(更佳為約800至1,500 ppm)氟離子者。
於許多具體例中,口腔組合物包含具有一或多種有助於降低例如牙齦炎、牙斑、結石、齲齒及/或敏感性之亞錫離子源之口腔護理劑。可存在有一或多種此等來源。適合的亞錫離子源包含(但不限於)氟化亞錫、其他鹵化物(例如氯化亞錫二水合物)、焦磷酸亞錫、有機羧酸亞錫鹽類(例如甲酸亞錫、醋酸亞錫、葡萄糖酸亞錫、乳酸亞錫、酒石酸亞錫、草酸亞錫、丙二酸亞錫及檸檬酸亞錫)、乙烯果綠定亞錫(stannous ethylene glyoxide)以及類似物。一或多種亞錫離子源係視情況且例示地以總含量為組成物重量之約0.01%至約10%(例如約0.1%至約7%,或約1%至約5%)存在。
於口腔組合物之某些具體例中,至少一種黃酮類化合物、至少一種黃烷以及含有亞錫離子源之口腔護理活性劑之組合可提供優越的抗牙齦炎功效。再者,至少一種自由-B-環黃酮類化合物和至少一種黃烷與亞錫離子源之組合似乎提供改良美觀之口腔組合物,係包含改良的顏色安定性。於一實施例中,口腔組合物包含約0.5%之UNIVESTIN、約0.45%之氟化亞錫以及約0.6%之氯化亞錫。
於許多具體例中,口腔組合物包含具有一或多種鋅離子源之口腔護理劑,其可用作例如抗微生物劑、抗結石劑或呼吸清新劑。適合的鋅離子源包含(但不限於)醋酸鋅、氯酸鋅、檸檬酸鋅、葡萄糖酸鋅、甘胺酸鋅、氧化鋅、硫酸鋅、檸檬酸鋅鈉以及類似物。一或多種鋅離子源係視情況且例示地以總含量為組成物重量之約0.05%至約3%(例如約0.1%至約1%)存在。
本發明之口腔組合物視情況包含一種有效於例如改善乾燥口腔之唾液興奮劑。可使用任一種口部可接受的唾液興奮劑,係包含(但不限於)食物酸,例如檸檬酸、乳酸、馬來酸、琥珀酸、抗壞血酸、己二酸、反丁烯二酸及酒石酸以及其混合物。一或多種唾液興奮劑係視情況以唾液興奮有效總含量存在。
本發明之組合物視情況包含H2
組胺酸受體拮抗劑。此中有效的H2
拮抗劑包含(但不限於)西咪替丁(cimetidine)、依汀替丁(etintidine)、雷尼替丁(ranitidine)、ICIA-5165、替沃替丁(tiotidine)、ORF-17578、魯比替丁(lupititidine)、東替丁(donetidine)、法莫替丁(famotidine)、羅沙替丁(roxatidine)、皮法替丁(pifatidine)、蘭替丁(lamtidine)、BL-6548、BMY-25271、扎替丁(zaltidine)、尼扎替丁(nizatidine)、咪芬替丁(mifentidine)、BMY-52368、SKF-94482、BL-6341A、ICI-162846、雷索替丁(ramixotidine)、Wy-45727、SR-58042、BMY-25405、羅西替丁(loxitidine)、DA-4634、比芬替丁(bisfentidine)、舒福替丁(sufotidine)、乙溴替丁(ebrotidine)、HE-30-256、D-16637、FRG-8813、FRG-8701、因普咪丁(impromidine)、L-643728、HB-408.4以及其混合物。
本發明之組合物視情況包含減敏劑。此中有效的減敏劑包含檸檬酸鉀、氯化鉀、酒石酸鉀、碳酸氫鉀、草酸鉀、硝酸鉀、鍶鹽以及其混合物。替代地或另外地,可使用局部或系統性止痛劑,例如阿斯匹靈、可待因、乙醯基胺基苯、草酸鈉或三乙醇胺草酸鹽。
本發明之組成物視情況包含營養劑。適合的營養劑包含維生素、礦物質、胺基酸以及其混合物。維生素包含維生素C及D、硫胺素、核黃素、泛酸鈣、菸鹼酸、葉酸、菸鹼醯胺、維生素B6、氰鈷胺素、對-胺基苯甲酸、生物黃酮類化合物以及其混合物。營養補充劑包含胺基酸(例如L-色胺酸、L-絲胺酸、甲硫胺酸、酥胺酸、左卡尼汀(levocarnitine)及L-卡尼汀)、解脂素(例如膽鹼、肌醇、甜菜鹼及亞麻油酸)、魚油(包含其成分,例如ω-3(N-3)聚不飽和脂肪酸、二十碳五烯酸(eicosapentaenoic acid)及二十二碳六烯酸(docosahexaenoic acid))以及其混合物。
口腔組合物亦包含至少一種抗結石活性劑,例如一或多種美國專利第5,292,526號(Gaffar等人)中所揭示之抗結石劑。於許多具體例中,組合物包含一或多種抗結石聚磷酸鹽。口腔組合物可包含至少一種以有效抗結石含量存在於口腔組合物中之完全或部分中和的鹼金屬或三聚磷酸銨或六偏磷酸鹽。口腔組合物亦可包含至少一種以有效抗結石含量存在之水溶性線型分子性脫水的聚磷酸鹽。口腔組合物亦可包含鉀和鈉鹽(至少之一係以有效抗結石含量存在)之混合物作為聚磷酸鹽抗結石劑。
抗結石組合物亦可包含以鉀和鈉鹽之混合物存在之有效抗結石含量之線型分子性脫水的聚磷酸鹽抗結石劑。於組合物中之鉀對鈉的比例可在例如約3:1之範圍內。聚磷酸鹽可以不同含量存在於口腔組合物中。口腔組合物的實例包含口腔護理活性劑,其中聚磷酸根離子對口腔護理劑的重量比例係於約0.7:1過量至小於約4:1之範圍內,或其中功效增強劑對聚磷酸根離子的重量比例係於約1:6至約2.7:1之範圍內,或其中功效增強劑對聚磷酸鹽的重量比例係於約1:6至約2.7:1之範圍內。其他有效的抗結石劑包含聚羧酸酯聚合物及聚乙烯基甲基醚/馬來酸酐(PVME/MA)共聚物,例如於以上之生物利用率增強劑本文中所討論之GANTREZ。
為了使口腔組合物的抗結石功效達到最佳,係合宜地存在有對抗聚磷酸鹽之酵素性水解之抑制劑。此等藥劑為足以供應25 ppm至5,000 ppm,或25 ppm至2,000 ppm氟離子之氟離子源(於含量為約0.01重量%至約5重量%時),以及0%至3%具有分子量為約1,000至約1,000,000(較佳為約30,000至約500,000)之合成陰離子聚合聚碳酸酯。
當經由最初將聚磷酸鹽和視需要選用的口腔護理抗菌劑溶解於濕潤劑和表面活性劑中,且遞增地添加生物利用率增強劑於所生成的口腔組合物中時(尤其於功效增強劑為聚合的聚羧酸酯時,例如GANTREZ),溶液變為透明,並且可描繪為”微乳液”。隨著此中之生物利用率增強劑的含量提高使得全部口腔組合物含有其重量之約2.2%,溶液變為混濁,並且可描繪為”巨乳液”。於此”巨乳液”型組合物中,視需要選用的抗菌劑之抗菌斑作用似乎是最佳的。
本發明之組合物視情況包含研磨劑。於許多具體例中,研磨劑係適用於例如作為拋光劑。可使用任一種口部可接受的研磨劑,但應選擇研磨劑的類型、細度(粒度)及含量,俾使得牙釉質於正常使用組合物下不會過度磨損。適合的研磨劑包含二氧化矽,例如呈矽膠、含水二氧化矽或沉澱二氧化矽、氧化鋁、不溶性磷酸鹽、碳酸鈣、樹脂性研磨劑(例如尿素-甲酫縮合產物)以及其混合物。適用於作為研磨劑之不溶性磷酸鹽為原磷酸鹽、聚偏磷酸鹽及焦磷酸鹽。此等之例示實例包含原磷酸二鈣二水合物、焦磷酸鈣、β-焦磷酸鈣、磷酸三鈣、聚偏磷酸鈣以及不溶性聚偏磷酸鈉。一或多種研磨劑係以研磨有效總量視情況地存在,係通常為組合物重量之約5%至約70%,例如約10%至約50%,或約15%至約30%。研磨劑(倘若存在時)的平均粒度通常為約0.1微米至約30微米,例如約1微米至約20微米,或約5微米至約15微米。
於某些具體例中,口腔組合物之口腔護理活性劑包含以下例示的額外口腔護理活性劑(未於上述討論者),係包含α-紫蘿蘭酮、葡萄籽提取物、百里香酚、丁香油酚、薄荷腦、香葉醇、香芹酚、檸檬醛、桉樹酚、8-羥基喹啉、酞酸及其鹽類(例如酞酸鎂一鉀)、血根鹼、水楊酸基苯胺、鹵化水楊酸基苯胺、度米芬(domiphen bromide)、磺胺劑、六氫吡啶基衍生物(例如地莫匹醇(delmopinol)及辛哌醇(octapinol))。
口腔組合物包含口部可接受的賦形劑或載體。載體可為液態、半固態或固相,呈漱口水、牙膏(包含牙膏、牙粉及預防糊劑)、糖果(包含錠劑及口香糖)、藥劑、薄膜形式或熟習本技藝之人士已知的形式。特定載體成分之選擇係取決於所欲的產品形式。
本發明之口腔組合物可經由技藝中已知的任一種用以合併成分製造口腔護理組合物方法製得。可用的方法之實例係揭示於:美國專利第6,403,059號(Martin等人);Clinical Pharmacology for Dental Professionals(Mosby-Year Book,Inc.,第3版,1989);Mosby’s Dental Hygiene:Concepts,Cases and Competencies,(Daniel,Susan J.,Harfst及Sherry A.編輯,Elsevier SCience Health Science Div.2002);以及Ernest W.Flick,Cosmetic and Toiletry Formulations,第2版。
可用以形成以上列示的載體之習知成分係為熟習本技藝之人士所熟知。可使用任一種適合的口部可接受之賦形劑,例如揭示於美國專利第4,894,220號(Nabi等人)。熟習本技藝之人士當可明白,除了先前描述的成分外,口腔組合物視情況包含其他材料,其包含例如表面活性劑(例如界面活性劑、乳化劑及泡沫調整劑)、黏度改質劑及增稠劑、濕潤劑、稀釋劑、額外的pH改質劑、軟化劑、潤膚膏、口感劑、增甜劑、調味劑、著色劑、防腐劑、溶劑(例如水)以及其組合。應瞭解雖然以上材料種類之每一者的一般特性可以不同,但是可有一些共同特性,並且任一種給定的材料可符合二或多種此等活性劑種類範圍內之多重目的。此等載體材料係根據活性成分之所有組份的相容性和安定性而選用,係包含自由-B-環黃酮類化合物及黃烷以及視需要選用一或多種供口腔組合物用之口腔護理活性劑化合物。再者,如上所述,載體成分亦可用作生物利用率增強劑(係為功效增強劑或供活性成分用之溶解劑)。
典型有效的表面活性劑係揭示於以上含有溶解劑之生物利用率增強劑本文中。表面活性劑通常為口腔組成物之重要態樣,因為其可發揮界面活性劑、乳化劑、泡沫調整劑及/或活性成分分散劑之功能。舉例來說,於口腔組合物具有含陽離子型活性口腔護理劑之活性成分的具體例中’載體較佳為含有非強陰離子性之界面活性劑(例如可結合於陽離子型活性成分而潛在地降低其生物利用率之陰離子型化合物)。適合的表面活性劑(包含於以上生物利用率/功效增強劑之本文中所討論者)係遍及廣泛pH範圍內為適度安定及發泡者。於某些具體例中,一或多種表面活性劑係於約0.001%至約5%之範圍內(較佳為約0.5%至約2.5%)存在於口腔組合物中。
口腔組合物亦包含增稠劑。可使用任一種熟習本技藝之人士已知之適合的增稠劑,例如揭示於美國專利第6,692,726號(Morgan等人)以及美國專利第6,696,047號(Scott等人)之增稠劑。一或多種增稠劑視情況地以總含量為口腔組合物重量之約0.01%至約15%(例如約0.1%至約10%或約0.2%至約5%)存在。
於其中口腔組合物呈漱口水形式之具體例中,例示的載體實質上是液態的。”漱口水”一詞包含洗液、噴霧、沖洗液、沖洗劑以及類似物。於此一製劑中,口部可接受的載體通常具有含水或水與醇混合物之水性相。再者,於許多具體例中,口腔載體通常具有濕潤劑、界面活性劑、pH緩衝劑以及增甜劑及/或調味劑(例如以上所揭示者)。
舉例來說,漱口水賦形劑可為水-醇混合物。一般而言,水對醇之重量比例係於約1:1至約20:1之範圍內,較佳為約3:1至10:1,更佳為約4:1至約6:1。於例如漱口水中之水-醇混合物的總含量通常係於約70至約99.9重量%之範圍內。醇較佳為無毒的,例如乙醇或異丙醇。濕潤劑,例如甘油、山梨醇或木糖醇,可以含量為約約10至約30重量%存在。口腔組合物可含有約5重量%至約30重量%之水。液態口腔組合物通常含有約50至85重量%之水,可含有約0.5至20重量%之醇,並且亦可含有約10至40重量%之濕潤劑(例如甘油、山梨醇及/或木糖醇)。一些材料係以水溶液形式於市面上出售’例如以70%水溶液提供之山梨醇。乙醇為一種較佳的無毒醇類。咸信醇類係輔助溶解水不溶性口腔護理劑以及自由-B-環黃酮類化合物和黃烷之混合物(於本質上係作為溶解劑)。
於其中口腔組合物呈糖果形式之具體例中,例示的載體實質上是固態或半固態的。糖果載體係為技藝中所熟知。就錠劑而言,載體通常包含錠劑基材(例如含有非致癌性多元醇及/或澱粉/糖衍生物)、乳化劑、潤滑劑、調味劑、增稠劑以及視需要選用塗覆材料。口香糖載體通常具有口香糖基劑、一或多種增塑劑、增甜劑以及調味劑。
於其中口腔組合物呈薄膜形式之具體例中,例示的載體實質上是固態或半固態的。一般而言,此等薄膜載體包含水溶性或可分散薄膜形成劑,例如親水性聚合物。薄膜載體視情況亦可包含疏水性薄膜形成聚合物,其係為可除式支持層或與親水性薄膜形成聚合物混合。薄膜載體視情況包含增塑劑、表面活性劑、填料、增體劑以及黏度改質劑。
於其中口腔組合物呈牙膏形式之具體例中,例示的載體實質上是固態或半固態的。牙膏通常含有表面活性劑、濕潤劑、黏度改質劑及/或增稠劑、研磨劑、溶劑(例如水)、調味劑以及增甜劑。
於牙膏之一具體例中,載體包含水相及濕潤劑。就某些牙膏而言,水和濕潤劑液相包含至少約10重量%之口腔組合物。再者,濕潤劑較佳含有丙二醇,其係用作生物利用率增強劑(即有助於溶解自由-B-環黃酮類化合物/黃烷混合物(及任一種實質上水不溶性口腔護理劑)之溶解劑)。於某些具體例中,剩餘的濕潤劑較佳為甘油及/或山梨醇及/或木糖醇。水通常係以至少約3重量%之含量存在;並且甘油及/或山梨醇及/或木糖醇通常合計為口腔組合物之約6.5至75重量%,更佳為約10至75重量%,並且合併溶解性濕潤劑時,濕潤劑成分通常合計為口腔組合物之約7至80重量%。再者,某些成分係以水溶液形式於市面上出售(例如以70%水溶液提供之山梨醇)。當組合物含有實質上為水不溶性非離子型抗菌口服護理劑時,組合物具有最小含量的聚乙二醇,尤其具有平均分子量為600或更多者,因為咸信聚乙二醇可抑制某些非陽離子型抗菌劑之抗菌活性,甚至當存再有另一種成分(例如丙二醇)以進行溶解作用時亦同。
於其中口腔組合物呈藥劑形式(例如非磨凝膠或軟膏)之具體例中,其可施於齒齦溝槽或邊緣,並且可合併傷口敷料、紗布、薄膜及類似物使用。此等凝膠可包含水性及非水性凝膠二者。水性凝膠通常包含聚合物基劑、增稠劑、濕潤劑、調味劑、增甜劑及溶劑(通常含水)。
本發明提供使用根據本發明之口腔組合物治療及抑制口腔狀態(例如發炎狀態、牙菌斑及牙結石,其全部可引起牙齦炎及/或牙周炎)之方法及程序。再者,本發明提供商業化包裝,俾散佈及貯存口腔組合物。
口腔組合物可依任一種技藝中已知之適合方式施於受試者。舉例來說,藉使用適合的塗藥器或傳送裝置(例如牙刷、牙條、薄膜、注射器、膠布、藥丸或任一種技藝中已知的其他塗藥器或傳送裝置),口腔組合物可施於受試者的口腔。組合物可用於預防方法及程序,俾促進和維持口腔健康、外觀及呼吸清新性。根據用以治療及/或抑制口腔發炎狀態、牙菌斑或牙結石之特殊治療進程,口腔組合物可重複地施於受試者超過若干日。關於治療進程之操作設定可提供於商業化包裝中。
本發明將進一步透過以下非限定實施例說明。
本發明之牙膏組合物係藉合併表1和2中詳列之成分而製得。
此中所揭示之實施例及其他具體例係為例示之用,而非用以限制說明本發明之組合物和方法之全部範圍。特殊具體例、材料、組合物及方法得施以相當的變化、修飾及改變皆不脫本發明之範圍,實質上獲得類似的結果。
Claims (44)
- 一種口腔組合物,其包含:自由-B-環黃酮類化合物;黃烷;以及供黃酮類化合物及/或黃烷用之生物利用率增強劑係為功效增強劑,其係選自聚合的聚羧酸酯、聚合的陰離子型膦酸鹽、及其組合,其中該組合物係呈潔牙劑、牙膏、牙膠、漱口水、洗口藥或口腔薄膜之形式,其中自由-B-環黃酮類化合物及黃烷之組合濃度為該組成物之0.001重量%至5重量%,且該生物利用率增強劑係以該組成物之0.0005至5重量%存在。
- 如申請專利範圍第1項之組合物,其中該功效增強劑係包含傳送增強基團及保留增強基團,其中該傳送增強基團係增強傳送該黃酮類化合物及該黃烷至口腔組織,並且該保留增強基團係增強口腔組織對該黃酮類化合物及該黃烷之保留率。
- 如申請專利範圍第1項之組合物,其中該生物利用率增強劑進一步包含溶解劑,其係選自醚類、酮類、二醇、脂肪、油脂、脂質、表面活性劑、酒精、保濕劑、吡咯烷酮、聚吡咯烷酮及其混合物。
- 如申請專利範圍第1項之組合物,其中該聚合的聚羧酸酯具有平均分子量為100至5,000,000,且該聚合的陰離子型膦酸鹽具有平均分子量為100至1,000,000。
- 如申請專利範圍第1項之組合物,其中該生物利用率增強劑包含馬來酸或酸酐與其他乙烯系不飽和可聚合單體之陰離子型共聚物。
- 如申請專利範圍第1項之組合物,進一步包含口腔護理活性劑,其係選自由以下物質所組成之群:抗菌劑、抗微生物劑、抗齲劑、抗牙垢劑、抗附著劑、生物膜分解劑、抗發炎劑、抗生素及其混合物。
- 如申請專利範圍第1項之組合物,進一步包含具有非離子型化合物之口腔護理活性劑。
- 如申請專利範圍第1項之組合物,進一步包含具有2’,4,4’-三氯-2-羥基-二苯醚(三氯生(triclosan))之口腔護理活性劑。
- 如申請專利範圍第1項之組合物,進一步包含具有活性化合物之口腔護理活性劑,該活性化合物係選自由以下物質所組成之群:苄索氯銨(benzethonium chloride)、奧替尼啶(octenidine)、海克替啶(hexetidine)、己咪定(hexamidine)、氯化十六基吡錠、氯己定(chlorhexidine)、阿來西定(alexidine)、Nα -椰油基-L-精胺酸甲基酯、Nα -椰油基-L-精胺酸乙基酯、Nα -椰油基-L-精胺酸丙基酯、Nα -硬脂醯基-L-精胺酸甲基酯、Nα -硬脂醯基-L-精胺酸乙基酯、Nα -月桂醯基-L-精胺酸乙基酯、2’,4,4’-三氯-2-羥基-二苯醚(三氯生(triclosan))、亞錫離子源、氟離子源、鋅離子源、鹽類及其混合物。
- 如申請專利範圍第1項之組合物,其中該自由-B-環黃 酮類化合物及該黃烷之存在量係分別為該組成物之0.001重量%至5重量%。
- 一種口腔組合物,其包含:自由-B-環黃酮類化合物;黃烷;及供黃酮類化合物及/或黃烷用之生物利用率增強劑,其中該生物利用率增強劑係為功效增強劑,其係選自聚合的聚羧酸酯、聚合的陰離子型膦酸鹽、及其組合;以及非離子型抗菌劑,其中該組合物係呈潔牙劑、牙膏、牙膠、漱口水、洗口藥或口腔薄膜之形式,其中自由-B-環黃酮類化合物及黃烷之組合濃度為該組成物之0.001重量%至5重量%,且該生物利用率增強劑係以該組成物計之0.0005至5重量%存在。
- 如申請專利範圍第11項之組合物,其中該非離子型抗菌劑為2’,4,4’-三氯-2-羥基-二苯醚(三氯生(triclosan))。
- 如申請專利範圍第11項之組合物,其中該該功效增強劑包含傳送增強基團及保留增強基團,其中該傳送增強基團係增強傳送該黃酮類化合物及該黃烷至口腔組織,並且該保留增強基團係增強口腔組織對該黃酮類化合物及該黃烷之保留率。
- 如申請專利範圍第11項之組合物,其中該生物利用率增強劑進一步包含選自醚類、酮類、二醇、脂肪、油 脂、脂質、表面活性劑、酒精、保濕劑、吡咯烷酮、聚吡咯烷酮及其混合物之溶解劑。
- 如申請專利範圍第11項之組合物,其中該聚合的聚羧酸酯具有平均分子量為100至5,000,000,且該聚合的陰離子型膦酸鹽具具有平均分子量為100至1,000,000。
- 如申請專利範圍第11項之組合物,進一步包含口腔護理活性劑,其係選自由以下物質所組成之群:抗菌劑、抗微生物劑、抗齲劑、抗牙垢劑、抗附著劑、生物膜分解劑、抗發炎劑、抗生素及其混合物。
- 如申請專利範圍第11項之組合物,進一步包含選自由以下物質所組成之群之口腔護理活性劑:苄索氯銨(benzethonium chloride)、奧替尼啶(octenidine)、海克替啶(hexetidine)、己咪定(hexamidine)、氯化十六基吡錠、氯己定(chlorhexidine)、阿來西定(alexidine)、Nα -椰油基-L-精胺酸甲基酯、Nα -椰油基-L-精胺酸乙基酯、Nα -椰油基-L-精胺酸丙基酯、Nα -硬脂醯基-L-精胺酸甲基酯、Nα -硬脂醯基-L-精胺酸乙基酯、Nα -月桂醯基-L-精胺酸乙基酯、亞錫離子源、氟離子源、鋅離子源、鹽類及其混合物。
- 如申請專利範圍第11項之組合物,其中該自由-B-環黃酮類化合物及該黃烷之存在量係分別為該組成物之0.001重量%至5重量%。
- 一種口腔組合物,其包含:自由-B-環黃酮類化合物; 黃烷;以及口腔護理活性劑,其中該組合物係呈潔牙劑、牙膏、牙膠、漱口水、洗口藥或口腔薄膜之形式,其中自由-B-環黃酮類化合物及黃烷之組合濃度為該組成物之0.001重量%至5重量%。
- 如申請專利範圍第19項之組合物,其中該自由-B-環黃酮類化合物及該黃烷係分別之存在量分別為該組成物之0.001重量%至5重量%。
- 如申請專利範圍第19項之組合物,其中該口腔用組合物包含存在量為0.001重量%至5重量%之口腔護理活性劑。
- 如申請專利範圍第19項之組合物,其中該口腔護理活性劑係選自由以下物質所組成之群:抗菌劑、抗微生物劑、抗齲劑、抗牙垢劑、抗附著劑、生物膜分解劑、抗發炎劑、抗生素及其混合物。
- 如申請專利範圍第19項之組合物,其中該口腔護理活性劑包含非離子型化合物。
- 如申請專利範圍第23項之組合物,其中該口腔護理活性劑包含2’,4,4’-三氯-2-羥基-二苯醚(三氯生(triclosan))。
- 如申請專利範圍第19項之組合物,其中該口腔護理活性劑包含選自由以下物質所組成之群之陽離子型活性成分:苄索氯銨(benzethonium chloride)、奧替尼啶(octenidine)、海克替啶(hexetidine)、己咪定 (hexamidine)、氯化十六基吡錠、氯己定(chlorhexidine)、阿來西定(alexidine)、Nα -椰油基-L-精胺酸甲基酯、Nα -椰油基-L-精胺酸乙基酯、Nα -椰油基-L-精胺酸丙基酯、Nα -硬脂醯基-L-精胺酸甲基酯、Nα -硬脂醯基-L-精胺酸乙基酯、Nα -月桂醯基-L-精胺酸乙基酯、2’,4,4’-三氯-2-羥基-二苯醚(三氯生(triclosan))、亞錫離子源、氟離子源、鋅離子源、鹽類及其混合物。
- 如申請專利範圍第19項之組合物,進一步包含供黃酮類化合物及/或黃烷用之生物利用率增強劑,其中該生物利用率增強劑係為功效增強劑,其係選自聚合的聚羧酸酯、聚合的陰離子型膦酸鹽、及其組合。
- 如申請專利範圍第26項之組合物,其中該功效增強劑係包含傳送增強基團及保留增強基團,其中該傳送增強基團係增強傳送該黃酮類化合物及該黃烷至口腔組織,並且該保留增強基團係增強口腔組織對該黃酮類化合物及該黃烷之保留率;該生物利用率增強劑進一步包含溶解劑,其係選自醚類、酮類、二醇、脂肪、油脂、脂質、表面活性劑、酒精、保濕劑、吡咯烷酮、聚吡咯烷酮及其混合物。
- 如申請專利範圍第26項之組合物,其中該聚合的聚羧酸酯具有平均分子量為100至5,000,000,且該聚合的陰離子型膦酸鹽具有平均分子量為100至1,000,000。
- 一種口腔組合物,其包含:自由-B-環黃酮類化合物; 黃烷;以及含有亞錫離子源之口腔護理活性劑,其中該組合物係呈潔牙劑、牙膏、牙膠、漱口水、洗口藥或口腔薄膜之形式,其中自由-B-環黃酮類化合物及黃烷之組合濃度為該組成物之0.001重量%至5重量%。
- 如申請專利範圍第29項之組合物,其中該亞錫離子之存在量係為該組成物之0.1重量%至10重量%。
- 如申請專利範圍第29項之組合物,其中該亞錫離子源包係選自由以下物質所組成之群:氟化亞錫、氯化亞錫、焦磷酸亞錫、甲酸亞錫、醋酸亞錫、葡萄糖酸亞錫、乳酸亞錫、酒石酸亞錫、草酸亞錫、丙二酸亞錫、檸檬酸亞錫、乙烯果綠定亞錫(stannous ethylene glyoxide)及其混合物。
- 如申請專利範圍第29項之組合物,進一步包含氟離子源及鋅離子源中之一或多種。
- 如申請專利範圍第29項之組合物,進一步包含額外的口腔護理活性劑。
- 如申請專利範圍第33項之組合物,該口腔護理活性劑係選自由以下物質所組成之群:抗菌劑、抗微生物劑、抗齲劑、抗牙垢劑、抗附著劑、生物膜分解劑、抗發炎劑、抗生素及其混合物。
- 如申請專利範圍第29項之組合物,進一步包含供黃酮類化合物及/或黃烷用之生物利用率增強劑,其係包含溶解劑與功效增強劑中之至少一種,其中該功效增強 劑係選自聚合的聚羧酸酯、聚合的陰離子型膦酸鹽、及其組合。
- 如申請專利範圍第29項之組合物,進一步包含具有著色劑之載體,其中該亞錫離子源促進該口腔組合物之著色安定性。
- 一種口腔用組合物,其包含:自由-B-環黃酮類化合物;黃烷;以及含有陽離子型化合物之口腔護理活性劑,其中自由-B-環黃酮類化合物及黃烷之組合濃度為該組成物之0.001重量%至5重量%。
- 如申請專利範圍第37項之組合物,其中該陽離子型化合物係選自由以下物質所組成之群:苄索氯銨(benzethonium chloride)、奧替尼啶(octenidine)、海克替啶(hexetidine)、己咪定(hexamidine)、氯化十六基吡錠、氯己定(chlorhexidine)、阿來西定(alexidine)、Nα -椰油基-L-精胺酸甲基酯、Nα -椰油基-L-精胺酸乙基酯、Nα -椰油基-L-精胺酸丙基酯、Nα -硬脂醯基-L-精胺酸甲基酯、Nα -硬脂醯基-L-精胺酸乙基酯、Nα -月桂醯基-L-精胺酸乙基酯、鹽類及其混合物。
- 如申請專利範圍第37項之組合物,其中該口腔護理活性劑包含乙基月桂醯基精胺酸鹽酸鹽(ELAH)。
- 如申請專利範圍第37項之組合物,進一步包含供黃酮類化合物及/或黃烷用之生物利用率增強劑,其係包含溶解劑與功效增強劑中之至少一種,其中該功效增強 劑係選自聚合的聚羧酸酯、聚合的陰離子型膦酸鹽、及其組合。
- 一種口腔組合物用於製造供抑制及/或治療哺乳動物受試者中之口腔發炎狀況的口腔護理產品之用途,其中該口腔組合物包含自由-B-環黃酮類化合物、黃烷以及用以提高黃酮類化合物及/或黃烷於口腔之口腔組織中之生物利用率增強劑,其中該生物利用率增強劑係為功效增強劑,其係選自聚合的聚羧酸酯、聚合的陰離子型膦酸鹽、及其組合,其中自由-B-環黃酮類化合物及黃烷之組合濃度為該組成物之0.001重量%至5重量%,且該生物利用率增強劑係以該組成物之0.0005至5重量%存在。。
- 如申請專利範圍第41項之用途,其中該自由-B-環黃酮類化合物及該黃烷之存在量係分別為該組成物之0.001重量%至5重量%。
- 如申請專利範圍第41項之用途,其中該聚合的聚羧酸酯具有平均分子量為100至5,000,000,且該聚合的陰離子型膦酸鹽具有平均分子量為100至1,000,000。
- 如申請專利範圍第41項之用途,其中該組合物進一步包含選自由以下物質所組成之群之口腔護理活性劑:抗菌劑、抗微生物劑、抗齲劑、抗牙垢劑、抗附著劑、生物膜分解劑、抗發炎劑、抗生素及其混合物。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63933104P | 2004-12-22 | 2004-12-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200637596A TW200637596A (en) | 2006-11-01 |
| TWI404545B true TWI404545B (zh) | 2013-08-11 |
Family
ID=37908523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW94145428A TWI404545B (zh) | 2004-12-22 | 2005-12-21 | 含有黃酮類化合物及黃烷之口腔護理組合物 |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN101141999A (zh) |
| AR (1) | AR052840A1 (zh) |
| MY (1) | MY151067A (zh) |
| TW (1) | TWI404545B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352553B (es) * | 2012-12-17 | 2017-11-29 | Colgate Palmolive Co | Composicion para el cuidado oral comprendiendo un compuesto de amadori. |
| ES2593618T3 (es) * | 2012-12-18 | 2016-12-12 | Sunstar Suisse Sa | Composición oral tópica para aliviar los síntomas de la boca seca y para el tratamiento de úlceras bucales |
| CN107468587B (zh) * | 2017-09-14 | 2020-09-22 | 好维股份有限公司 | 一种包含稳定多酚的口腔护理组合物 |
| CN108929247A (zh) * | 2018-06-08 | 2018-12-04 | 中南大学 | 一种Nα-烷基酰精氨酸酯抗菌剂及其制备和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894220A (en) * | 1987-01-30 | 1990-01-16 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
| US5094842A (en) * | 1989-10-06 | 1992-03-10 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Oral compositions |
| WO2002047615A2 (en) * | 2000-12-13 | 2002-06-20 | University Of Rochester | Oral compositions and use thereof |
| US20030216481A1 (en) * | 2002-04-30 | 2003-11-20 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
| TW200630102A (en) * | 2004-10-19 | 2006-09-01 | Unigen Pharmaceuticals Inc | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
-
2005
- 2005-12-21 CN CNA2005800482732A patent/CN101141999A/zh active Pending
- 2005-12-21 TW TW94145428A patent/TWI404545B/zh not_active IP Right Cessation
- 2005-12-21 AR ARP050105463 patent/AR052840A1/es unknown
- 2005-12-22 MY MYPI20056126 patent/MY151067A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894220A (en) * | 1987-01-30 | 1990-01-16 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
| US5094842A (en) * | 1989-10-06 | 1992-03-10 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Oral compositions |
| WO2002047615A2 (en) * | 2000-12-13 | 2002-06-20 | University Of Rochester | Oral compositions and use thereof |
| US20030216481A1 (en) * | 2002-04-30 | 2003-11-20 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
| TW200630102A (en) * | 2004-10-19 | 2006-09-01 | Unigen Pharmaceuticals Inc | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200637596A (en) | 2006-11-01 |
| AR052840A1 (es) | 2007-04-04 |
| CN101141999A (zh) | 2008-03-12 |
| MY151067A (en) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005319184C1 (en) | Oral care compositions containing free-B-ring flavonoids and flavans | |
| US20070253919A1 (en) | Oral compositions comprising siloxane polymers | |
| TWI399217B (zh) | 含木糖醇之抗齲齒口腔護理組合物 | |
| TWI396557B (zh) | 含有未氧化山茶花(camellia)萃取物之口腔保健組成物 | |
| CN101132761B (zh) | 抗氧化洁齿剂组合物 | |
| CA2591998A1 (en) | Anti-caries oral care composition with a chelating agent | |
| EP1830821B1 (en) | Two phase toothpaste composition | |
| US20060140883A1 (en) | Oral care compositions containing a eucalyptus extract | |
| EP1835883A2 (en) | Two phase whitening oral care composition | |
| TWI404545B (zh) | 含有黃酮類化合物及黃烷之口腔護理組合物 | |
| CA2822027C (en) | Halogenated biphenols as antibacterial agents | |
| HK1154820A (zh) | 含有無取代b環黃酮和黃烷的口腔護理組成物 | |
| CN104135992B (zh) | 口腔护理组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |